These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036 [TBL] [Abstract][Full Text] [Related]
5. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634 [TBL] [Abstract][Full Text] [Related]
11. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999 [TBL] [Abstract][Full Text] [Related]
12. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. Andrews N; Stowe J; Kirsebom F; Toffa S; Rickeard T; Gallagher E; Gower C; Kall M; Groves N; O'Connell AM; Simons D; Blomquist PB; Zaidi A; Nash S; Iwani Binti Abdul Aziz N; Thelwall S; Dabrera G; Myers R; Amirthalingam G; Gharbia S; Barrett JC; Elson R; Ladhani SN; Ferguson N; Zambon M; Campbell CNJ; Brown K; Hopkins S; Chand M; Ramsay M; Lopez Bernal J N Engl J Med; 2022 Apr; 386(16):1532-1546. PubMed ID: 35249272 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age. Tan SHX; Cook AR; Heng D; Ong B; Lye DC; Tan KB N Engl J Med; 2022 Aug; 387(6):525-532. PubMed ID: 35857701 [TBL] [Abstract][Full Text] [Related]
14. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402 [TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents. Wu Q; Tong J; Zhang B; Zhang D; Chen J; Lei Y; Lu Y; Wang Y; Li L; Shen Y; Xu J; Bailey LC; Bian J; Christakis DA; Fitzgerald ML; Hirabayashi K; Jhaveri R; Khaitan A; Lyu T; Rao S; Razzaghi H; Schwenk HT; Wang F; Gage Witvliet MI; Tchetgen Tchetgen EJ; Morris JS; Forrest CB; Chen Y Ann Intern Med; 2024 Feb; 177(2):165-176. PubMed ID: 38190711 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years. Tartof SY; Frankland TB; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM JAMA Netw Open; 2022 Aug; 5(8):e2225162. PubMed ID: 35921109 [TBL] [Abstract][Full Text] [Related]
20. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study. Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]